RxDoctor Payments Data

Nyi Nyi Aung, MD

Internal Medicine · Brooklyn, NYNPI 1114344017

Payments from drug & device makers

$2,847in general payments, 2019–2025

Across 111 payments — averaging $25.65 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$897
  • Amgen$398
  • GSK$210
  • Takeda Pharmaceuticals U.S.A., Inc.$202
  • Gilead$167
  • Novartis$149
  • plus $825 from 17 others

What the payments were for

  • Food & beverage$2,847100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,847 in reported general payments places this provider in the 80th percentile of 9,771 internal medicine providers in New York.

See all internal medicine providers in New York

Medicare billing

Part B allowed, 2024
$77,632
Medicare patients
109
Services billed
1,253

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
FarxigaDapagliflozin Propanediol135$117,371
VascepaIcosapent Ethyl103$63,118
VemlidyTenofovir Alafenamide36$54,856
ProliaDenosumab30$49,699
JanuviaSitagliptin Phosphate46$47,399
OzempicSemaglutide42$41,599
JardianceEmpagliflozin47$40,782
TrulicityDulaglutide26$33,955
Diclofenac Epolamine54$31,837
EliquisApixaban26$18,382
Metformin Er GastricMetformin Hcl11$15,894
DapagliflozinDapagliflozin Propanediol19$15,490
MounjaroTirzepatide11$13,686
CreonLipase/Protease/Amylase16$13,295
Bydureon BciseExenatide Microspheres12$11,549

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaFarxiga$897$117,371135 claims
GileadVemlidy$167$54,85636 claims
AmgenProlia$398$49,69930 claims
Lilly USA, LLCTrulicity, Mounjaro$61$47,64137 claims
MerckJanuvia$103$47,39946 claims
Novo NordiskOzempic$81$41,59942 claims
AbbVieCreon, Restasis$68$20,86528 claims
GSKShingrix$210$3,23116 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 9,771 internal medicine providers in New York.

Other internal medicine in Brooklyn

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →